title: SR31747A: a peripheral sigma ligand with potent antitumor activities.
abstract: SR31747A is currently being evaluated in phase IIb clinical trials for prostate cancer treatment. The molecule is a peripheral sigma ligand that binds four proteins in human cells, i.e. SRBP-1, sigma-2, HSI and its relative SRBP-2. SR31747A is a dual agent with both immunomodulatory and antiproliferative activities. The molecule blocks proliferation of human and mouse lymphocytes, modulates the expression of pro- and anti-inflammatory cytokines, and was shown to protect animals in vivo against acute and chronic inflammatory conditions such as acute graft-versus-host reaction, lethality induced by staphylococcal enterotoxin B and lipopolysaccharide or rheumatoid arthritis. Besides these immunomodulatory activities, the molecule also inhibits the proliferation of various tumor cell lines in vitro in a time- and concentration-dependent manner. In vivo, SR31747A has potent antitumoral activity as demonstrated against mammary and prostatic tumoral cell lines injected into nude mice, where both tumor incidence and growth were decreased by more than 40% following daily SR31747A treatment at 25 mg/kg i.p. The recent literature on SR31747A in cancer is reviewed here. We focus specifically on preclinical data obtained in vivo and on studies aimed at deciphering the mode of action of the molecule.
authors.affiliation: Immunology-Oncology Department, Sanofi-Synthelabo Recherche, 371 rue du Professeur Joseph Blayac, 34184 Montpellier Cedex 04, France. pierre.casellas@sanofi-synthelabo.com
authors.forename: Pierre
authors.initials: P
authors.lastname: Casellas
authors.forename: Sylvaine
authors.initials: S
authors.lastname: Galiegue
authors.forename: Bernard
authors.initials: B
authors.lastname: Bourrie
authors.forename: Jean-Bernard
authors.initials: JB
authors.lastname: Ferrini
authors.forename: Omar
authors.initials: O
authors.lastname: Jbilo
authors.forename: Hubert
authors.initials: H
authors.lastname: Vidal
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003510:Cyclohexanes / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy; D017480:Receptors, sigma / Q000187:drug effects* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D003510:Cyclohexanes; D007155:Immunologic Factors; D017480:Receptors, sigma; C088447:SR 31747